Prices of 56 drugs to come down; NPPA fixes ceiling rates - (Business Standard via NewsPoints Desk)

  • India's National Pharmaceutical Pricing Authority (NPPA) has capped the prices of 56 drugs used to treat cancer, diabetes, bacterial infections and hypertension, reducing the cost by an average of nearly 25 percent, reported Business Standard.

  • Companies such as Abbott, Cipla, Lupin, Alembic, Alkem Laboratories, Novartis, Biocon, Intas Pharmaceuticals, Hetero Healthcare and Ranbaxy, which is now owned by Sun Pharmaceutical, will be affected by the new measure.

  • "In some cases the reduction is 10 percent to 15 percent, while for others it is up to 45 percent to 50 percent," commented NPPA chairman Bhupendra Singh.

To read more NewsPoints articles, click here.

Reference Articles